This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Jun 22;359(9324):2202; author reply 2203-4.

doi: 10.1016/s0140-6736(02)09075-x.

Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study

J R Cockcroft, M J Brown

PMID: 12091008
DOI: 10.1016/s0140-6736(02)09075-x

Comment

Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study

J R Cockcroft et al. Lancet. 2002.

. 2002 Jun 22;359(9324):2202; author reply 2203-4.

doi: 10.1016/s0140-6736(02)09075-x.

Authors

J R Cockcroft, M J Brown

PMID: 12091008
DOI: 10.1016/s0140-6736(02)09075-x

No abstract available

PubMed Disclaimer

Comment on

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information